产品
编 号：F068833
分子式：C10H16N2O4S3
分子量：324.44
分子式：C10H16N2O4S3
分子量：324.44
产品类型
规格
价格
是否有货
结构图
CAS No: 120279-96-1
产品详情
生物活性：
Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
体内研究：
Dorzolamide (3, 10, or 30 mg/kg/day, ip) synergized mitomycin C exhibits anti-tumor activity in EAC solid tumor models. Dorzolamide produces a dose-dependent decrease in the calculated ratio (relative value of 57.3±1, 25.5±1.8, and 24.3± 0.7 %, respectively).Animal Model:Female Swiss albino mice (EAC solid tumor).
Dosage:3, 10, or 30 mg/kg/day (synergized mitomycin C).
Administration:IP, daily for 3 weeks.
Result:Upregulated TXNIP and p53 while downregulated bcl-2.Effective in retarding the growth of EAC in mice.
体外研究：
Component A, caused by an inward flux of CO2 and its subsequent hydration by CA-II, is blocked by Dorzolamide in a dose-dependent manner with an 50% inhibitory concentration IC50 of 2.4 μM (95% confidence interval: 0.5-10.85 μM).
Dorzolamide (L671152) is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
体内研究：
Dorzolamide (3, 10, or 30 mg/kg/day, ip) synergized mitomycin C exhibits anti-tumor activity in EAC solid tumor models. Dorzolamide produces a dose-dependent decrease in the calculated ratio (relative value of 57.3±1, 25.5±1.8, and 24.3± 0.7 %, respectively).Animal Model:Female Swiss albino mice (EAC solid tumor).
Dosage:3, 10, or 30 mg/kg/day (synergized mitomycin C).
Administration:IP, daily for 3 weeks.
Result:Upregulated TXNIP and p53 while downregulated bcl-2.Effective in retarding the growth of EAC in mice.
体外研究：
Component A, caused by an inward flux of CO2 and its subsequent hydration by CA-II, is blocked by Dorzolamide in a dose-dependent manner with an 50% inhibitory concentration IC50 of 2.4 μM (95% confidence interval: 0.5-10.85 μM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备